News: the clinical trial of Cuba’s novel coronavirus candidate vaccine is progressing smoothly

[Cuban news agency reported on July 31] on July 31, Eduardo mart í Nez D í AZ, President of the Cuban biotechnology and Pharmaceutical Group (biocubaarma), announced that the clinical trial of Cuba’s novel coronavirus vaccine “sovereign 01” was progressing smoothly

.

Martinez DIAS stressed that the experiment called “soberana Centro” began on Monday, July 26, in the cities of palmira and cruces in Cienfuegos province

.

In his tweet published on July 31, he stressed that the Cuban biotechnology and Pharmaceutical Group will continue to promote the research and development of the novel coronavirus vaccine“‘ The clinical trial of “central sovereignty” began on Monday, 26 July, the day of national rebellion, and is being carried out as planned in the cities of palmira and cruces in the province of cienfugos

.

We will continue to promote the novel coronavirus vaccine R & D strategy

.

“—— On July 31, 2021, another clinical trial was carried out by Eduardo Martinez (@ BCF) in Havana province

.

He also added that Camaguey’s “ismaelillo” test was also carried out smoothly

.

He stressed that the “pediatric sovereignty” and “Ismail Rio” trials involve pediatric populations of different ages, and they have successfully vaccinated the second dose of these vaccines“ We are continuing to promote the “pediatric sovereignty” trial in Havana

.

We have also made new progress in the ‘Ismail Rio’ test in camaguei

.

Both are suitable for pediatric populations

.

The second dose of these vaccines is in use and is safe

.

“—— Eduardo Martinez DIAS (@ edmartbcf) conducted the phase II clinical trial of candidate vaccine “sovereignty 01” in Cienfuegos Province on July 31, 2021, which was called “central sovereignty”, and 1166 subjects were included in the study; In addition, the “pediatric sovereignty” clinical trial in Havana will use three doses of vaccine for 350 children and adolescents, including candidate vaccines “sovereignty 02” (soberana02) and “sovereignty +” (soberanaplus)

.

At the same time, in the “Ismail Rio” trial, the subjects using the “abdala” vaccine include paediatric people aged 3 to 18

.

A total of about 600 camagui people will participate in the two stages of the trial.

.